Weight-loss surgery and medicine for atrial fibrillation in people with obesity
Tests weight-loss surgery or weight-loss medicine in adults with atrial fibrillation and obesity.
Key facts
- Who runs it
- Ali Aminian
- Where
- Cleveland, United StatesSee the site
- Trial code
- Registry title
- Metabolic Surgery for Atrial Fibrillation Elimination
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 100 people, planned
- Started
- 1 Nov 2026
- Expected to end
- 31 Mar 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
- Anti-Obesity Medication (AOM) treatment
- Record updated
- 17 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with symptomatic atrial fibrillation and a BMI of 35 to 65 who could have weight-loss (metabolic) surgery.
- Age
- 18 to 80 years old
- Sex
- All sexes
- Disease stage
- Symptomatic atrial fibrillation (paroxysmal, persistent or longstanding) shown on a heart monitor, with a burden of at least 1% over a 2-week screening and confirmed by an expert cardiologist. Paroxysmal AF needs at least one episode of 5 minutes or more in the last 3 months.
- Earlier treatment
- People with no prior AF ablation, or with a failed prior AF ablation, can join. People with type 2 diabetes must have been on a stable dose of diabetes medicine for at least 3 months. Prior bariatric or metabolic surgery of any kind is not allowed (a gastric balloon or band removed more than 1 year before enrollment is allowed).
- Biomarker or test result
- BMI of 35 to 65 kg/m2. For people with type 2 diabetes, HbA1c of 12% (108 mmol/mol) or lower.
Main reasons for not taking part
- Prior bariatric or metabolic surgery
- Type 1 or autoimmune diabetes
- Solid organ transplant, or eGFR below 30 or on dialysis
- Heart attack, stroke or heart surgery in the past 6 months, or NYHA Class IV
- Pregnant, breast-feeding or not using reliable contraception
The registry criteria, word for word
Show all 36 criteriaShow less
Who can take part
- Entry into the study would require that the patient:
- Is a candidate for general anesthesia
- Is eligible for metabolic surgery (RYGB or SG)
- Is ≥18 and ≤80 years old
- has a BMI ≥35 and ≤65 kg/m2
- has AF criteria, which:; Must be documented by EKG or cardiac monitor or Zio XT Patch; Must have symptomatic AF; In terms of types of AF, either paroxysmal AF with at least one episode lasting ≥5 minutes in the last 3 months prior to screening, or persistent AF, or longstanding AF; Must have a minimum burden of 1% during a 2-week screening time with an ambulatory noninvasive cardiac monitor; Must be assessed and confirmed by an expert cardiologist (e.g., cardiac electrophysiologist) to meet eligibility
- Patients without history of prior AF ablation/PVI procedure or with history of prior failed AF ablation/PVI procedure are eligible for the study
- Patients with and without T2DM are eligible for the study. Patients with T2DM should have been on a stable dose of anti-diabetic medication (including insulin) for at least 3 months prior to entry, with HbA1c ≤12%
- Have the ability and willingness to participate in the study and agree to any of the arms involved in the study
- Able to understand the options and to comply with the requirements of each arm
- Have a negative urine pregnancy test at screening and randomization visits for women of childbearing potential
- Women, of childbearing age, must agree to use reliable method of contraception for 2 years
Who cannot take part
- Prior bariatric and metabolic surgery of any kind (patients who had a gastric balloon or gastric band that were removed more than one year prior to enrollment are allowed to participate)
- Use of investigational therapy
- Life expectancy less than 3 years due to concomitant diseases
- Significant cardiac valvular disease (planned to undergo cardiac valve intervention/surgery in the next 12 months)
- Significant atherosclerotic disease (planned to undergo coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)
- Severe uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V
- Classified as New York Heart Association Class IV
- Hospitalization for myocardial infarction, unstable angina, stroke, transient ischemic attack, heart surgery, coronary stent placement in the past 6 months
- History of solid organ transplant
- Type 1 diabetes or autoimmune diabetes
- Decompensated cirrhosis characterized by ascites, hepatic encephalopathy, portal hypertension, or esophageal varices
- Presence of active malignancy (except non-melanoma skin cancer)
- Major mental health, psychological disorders, or substance abuse disorders that in the opinion of the investigators could disqualify the patient from metabolic surgery
- Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study
- Known adhesive allergies
- Left ventricular ejection fraction <20% at the time of screening
- eGFR < 30 mL/min/1.73 m2 at screening or being on dialysis
- Anemia defined as hemoglobin less than 9 g/dL
- Liver transaminase level >300 U/L
- Significant alcohol use (average >2 drinks/day)
- Unable to understand the risks, benefits and compliance requirements of study
- Lack capacity to give informed consent
- Plans to move outside the primary location of study (Northeast Ohio) within the next 12 months
- Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in United States
- The Cleveland ClinicCleveland, United StatesContact: Chytaine HallNot yet recruiting
About the trial
What the trial wants to find out
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation.
Read full original descriptionShow less
The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.
The 2 groups in the trial
- Metabolic SurgeryExisting treatment, for comparison
Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG)
Treatment: Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
- Control group (nonsurgical standard of care for obesity)Other group
In the Control group, the subjects will be receiving standard of care for nonsurgical management of obesity, including possible AOMs that are not contraindicated in patients with AF at the discretion of obesity medicine specialists.
Treatment: Anti-Obesity Medication (AOM) treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy of Cardiometabolic Risk Factor Control Through Metabolic Surgery on Management and Severity of Atrial Fibrillation: METSAFE Randomized Clinical Trial
- Plain-language title
- Weight-loss surgery and medicine for atrial fibrillation in people with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07027969, who can take part
- Record updated
- 17 April 2026